DUARTE, Calif.--(BUSINESS WIRE)--Feb. 3, 2006--Calando Pharmaceuticals Inc. announced today that it has established a collaborative development program relating to RNAi-based therapeutics with the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The terms of the development will be governed by a Letter of Intent to a Cooperative Research and Development Agreement (CRADA) that is currently being finalized by Calando and the NCI. Calando, a privately-held biopharmaceutical company that is majority owned by Arrowhead Research Corporation (Nasdaq:ARWR), was formed to develop and commercialize proprietary technologies for the therapeutic use of RNA interference, or "RNAi."
